Emerald Mutual Fund Advisers Trust Biomarin Pharmaceutical Inc Transaction History

Emerald Mutual Fund Advisers Trust

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 05, 2024	BUY	$76.22 - $98.51 $44,360 - $57,332	582 Added 61.39%	1,530 $147,000
Q3 2023 Oct 26, 2023	SELL	$85.07 - $94.48 $1,786 - $1,984	-21 Reduced 2.17%	948 $83,000
Q2 2023 Aug 10, 2023	BUY	$86.68 - $100.3 $83,992 - $97,190	969 New	969 $83,000
Q4 2022 Feb 03, 2023	BUY	$80.93 - $108.63 $84,895 - $113,952	1,049 New	1,049 $108,000

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Emerald Mutual Fund Advisers Trust, based on Form 13F filings with the SEC.

Stay updated on Emerald Mutual Fund Advisers Trust with notifications on news.